Renal Physiology & Tubular Function

📋 Key Information Summary

📋

Glomerular filtration rate (GFR) is the volume of plasma filtered by all functioning glomeruli per unit time; normal adult GFR is approximately 90–120 mL/min/1.73 m², estimated clinically using CKD-EPI 2021 creatinine equation (without race variable) in Australian laboratories.
Renal blood flow is autoregulated between mean arterial pressures of ~80–180 mmHg via the myogenic response (afferent arteriole) and tubuloglomerular feedback (macula densa sensing NaCl delivery to the distal nephron).
The proximal tubule reabsorbs ~65% of filtered Na⁺, ~85% of filtered HCO₃⁻, and virtually 100% of filtered glucose and amino acids via sodium-coupled co-transporters (SGLT2/SGLT1, EAAT, Na⁺-coupled amino acid carriers).
Proximal tubular HCO₃⁻ reclamation depends on luminal carbonic anhydrase IV and intracellular carbonic anhydrase II; inhibition by acetazolamide causes bicarbonaturia and metabolic acidosis.
The thick ascending limb of the loop of Henle (TAL) reabsorbs ~25% of filtered NaCl via the NKCC2 (Na⁺-K⁺-2Cl⁻) transporter — the target of loop diuretics such as furosemide.
The TAL is impermeable to water, generating the corticomedullary osmotic gradient essential for urinary concentration; dysfunction causes nephrogenic diabetes insipidus.
The distal convoluted tubule (DCT) reabsorbs ~5% of filtered NaCl via the NCC (Na⁺-Cl⁻ co-transporter) — the target of thiazide diuretics.
The collecting duct is the principal site of aldosterone-mediated Na⁺ reabsorption (ENaC) and K⁺ secretion (ROMK channels); also the site of ADH-regulated water reabsorption via aquaporin-2 (AQP2).
The countercurrent multiplication system (loop of Henle) and countercurrent exchange (vasa recta) maintain a medullary interstitial osmolality of ~300–1200 mOsm/kg, enabling urine concentration up to ~1200 mOsm/kg.
Prescribing implications: NSAIDs disrupt autoregulation (afferent vasoconstriction); ACE inhibitors reduce efferent tone — both lower GFR and can precipitate acute kidney injury, especially in combination.
Understanding tubular physiology underpins safe drug dosing: renally excreted medications require dose adjustment when eGFR <60 mL/min/1.73 m²; the Australian Medicines Handbook (AMH) provides standardised guidance.
SGLT2 inhibitors (dapagliflozin, empagliflozin) exploit proximal tubular physiology to induce glycosuria and natriuresis; now PBS-listed for CKD with eGFR ≥20 mL/min/1.73 m² in Australia.
Aboriginal and Torres Strait Islander peoples experience CKD at 2–3 times the rate of non-Indigenous Australians, making understanding of tubular physiology critical for culturally safe chronic kidney disease management.

Introduction & Australian Epidemiology

Understanding renal physiology — including glomerular filtration rate regulation, tubular transport mechanisms, and electrolyte handling — is fundamental to interpreting kidney disease, prescribing safely, and managing fluid and electrolyte disorders in clinical practice. The kidney performs excretory, homeostatic, endocrine (erythropoietin, calcitriol), and metabolic functions, with each nephron segment performing specialised transport tasks.

Chronic kidney disease (CKD) affects approximately 1.7 million Australians, with prevalence increasing with age: roughly 20% of adults aged ≥65 years have an eGFR <60 mL/min/1.73 m² (AIHW, 2023). Acute kidney injury (AKI) complicates 10–15% of hospital admissions and up to 50–60% of intensive care unit admissions in Australian tertiary centres. The burden is not equally distributed — Aboriginal and Torres Strait Islander peoples experience end-stage kidney disease (ESKD) at 4–8 times the rate of non-Indigenous Australians, with onset approximately 20 years earlier.

This guideline reviews renal physiology at each nephron segment, emphasising clinical correlations relevant to Australian primary care, emergency medicine, and specialist nephrology practice. Knowledge of where drugs act along the nephron enables rational diuretic prescribing, understanding of drug-induced nephrotoxicity, and appropriate dose adjustment in renal impairment.

ℹ️

Australian eGFR reporting: All Australian pathology laboratories now report eGFR using the CKD-EPI 2021 creatinine equation (race-free) as mandated by the RCPA. Units are mL/min/1.73 m². A persistent eGFR <60 mL/min/1.73 m² for ≥3 months defines CKD Stage ≥3a.

GFR & Renal Autoregulation

Glomerular Filtration Rate

GFR is determined by the net ultrafiltration pressure across the glomerular capillary wall, governed by the Starling equation:

🧮

Starling equation for GFR: GFR = K_f × (P_GC − P_BC) − (π_GC − π_BC)
where K_f = ultrafiltration coefficient (hydraulic permeability × surface area), P_GC = glomerular capillary hydrostatic pressure (~60 mmHg), P_BC = Bowman's capsule hydrostatic pressure (~18 mmHg), π_GC = glomerular capillary oncotic pressure (~28 mmHg rising to ~35 mmHg at efferent end), π_BC ≈ 0 (negligible protein filtration).

The normal single-nephron GFR (SNGFR) is approximately 40–60 nL/min; total GFR across ~1 million nephrons per kidney is approximately 90–120 mL/min/1.73 m² in a healthy young adult.

Determinants of GFR

Factor	Effect on GFR	Clinical Example
Afferent arteriolar constriction	↓↓ GFR	NSAIDs, high sympathetic tone, hypercalcaemia
Afferent arteriolar dilation	↑ GFR	Prostaglandins (PGI₂, PGE₂), low-dose dopamine
Efferent arteriolar constriction	↑ GFR (initially)	Angiotensin II, noradrenaline
Efferent arteriolar dilation	↓ GFR	ACE inhibitors / ARBs
↓ Plasma oncotic pressure	↑ GFR	Nephrotic syndrome (hypoalbuminaemia)
↑ Bowman's capsule pressure	↓↓ GFR	Urinary obstruction, tubular obstruction (casts)
↓ Renal plasma flow	↓ GFR	Hypovolaemia, heart failure, hepatorenal syndrome

Autoregulation Mechanisms

Renal blood flow (RBF) and GFR are maintained relatively constant over a wide range of mean arterial pressures (~80–180 mmHg) via two primary mechanisms:

1. Myogenic Response (Bayliss Effect)

An increase in perfusion pressure stretches the afferent arteriolar smooth muscle, triggering mechanosensitive ion channel activation, calcium influx, and vasoconstriction — thereby preventing a rise in glomerular capillary pressure and GFR. This response occurs within seconds. Conversely, reduced perfusion pressure causes afferent relaxation.

2. Tubuloglomerular Feedback (TGF)

The macula densa, a specialised epithelial plaque in the early distal tubule (at the junction of TAL and DCT), senses luminal NaCl concentration via the NKCC2 transporter:

↑ NaCl delivery to macula densa → ATP/adenosine release → afferent arteriolar constriction → ↓ GFR (negative feedback, preventing Na⁺ wasting).
↓ NaCl delivery to macula densa → reduced ATP release + prostaglandin/NO release → afferent dilation + renin release from juxtaglomerular (granular) cells → ↑ angiotensin II → efferent constriction → preserved GFR + ↑ Na⁺ reabsorption.

⚠️

Clinical significance — "Triple Whammy" risk: The combination of an ACE inhibitor (or ARB) + NSAID + diuretic dramatically impairs renal autoregulation. The ACEi dilates the efferent arteriole, the NSAID removes prostaglandin-mediated afferent dilation, and the diuretic causes volume depletion → high risk of precipitous AKI. This combination should be avoided, particularly in elderly patients and those with pre-existing CKD. The RACGP and Australian Commission on Safety and Quality in Health Care (ACSQHC) have issued alerts regarding this prescribing combination.

GFR Measurement & Estimation in Australia

Method	Details	Availability
CKD-EPI 2021 creatinine (recommended)	Uses serum creatinine, age, sex; no race coefficient. Validated in Australian populations. Reported automatically by all Australian labs.	Universal
CKD-EPI cystatin C	Less affected by muscle mass. Useful when creatinine-based eGFR unreliable (extremes of body habitus, amputees, cirrhosis).	Request test — MBS item 66823
Iohexol or iothalamate clearance (measured GFR)	Gold-standard measurement. Requires IV contrast agent and serial plasma sampling.	Specialist / research
24-hour urine creatinine clearance	Overestimates GFR due to tubular creatinine secretion. Largely superseded by eGFR equations.	Universal — but rarely recommended

Proximal Tubule Function (Glucose, Amino Acids, HCO₃⁻)

The proximal tubule (PT) is the workhorse of the nephron, responsible for reabsorbing approximately 65% of filtered Na⁺ and water, ~85% of filtered HCO₃⁻, and virtually 100% of filtered glucose and amino acids. It also performs organic anion and cation secretion (drug elimination), gluconeogenesis, ammoniagenesis, and 1α-hydroxylation of 25-hydroxyvitamin D.

Sodium & Water Reabsorption

The basolateral Na⁺/K⁺-ATPase maintains a low intracellular [Na⁺], driving luminal Na⁺ entry through multiple co-transporters and exchangers:

Na⁺/H⁺ exchanger (NHE3): Accounts for ~2/3 of proximal Na⁺ reabsorption; also mediates H⁺ secretion for HCO₃⁻ reclamation. Angiotensin II stimulates NHE3.
SGLT2 (S5a segment, early PT): Low-affinity, high-capacity Na⁺-glucose co-transporter; reabsorbs ~90% of filtered glucose. Target of SGLT2 inhibitors.
SGLT1 (S3 segment, late PT): High-affinity, low-capacity Na⁺-glucose co-transporter; reabsorbs remaining ~10% of glucose.
Na⁺-amino acid co-transporters: Multiple families (EAAT for acidic amino acids, B⁰AT1 for neutral amino acids, etc.) — virtually 100% reabsorption.

Glucose Handling

Filtered glucose is freely filtered at the glomerulus and entirely reabsorbed in the proximal tubule up to a transport maximum (T_m) of approximately 375 mg/min in males and 300 mg/min in females. The threshold plasma glucose at which glucosuria appears is approximately 10–11 mmol/L (slightly below T_m due to nephron heterogeneity — a "splay" in the titration curve).

💊

SGLT2 inhibitors — pharmacological exploitation of PT physiology: Dapagliflozin (Forxiga®), empagliflozin (Jardiance®), and canagliflozin (Invokana®) block SGLT2 in the early proximal tubule, causing glycosuria (~60–80 g glucose/day) and mild natriuresis. Originally developed for T2DM, they are now PBS-listed for:

CKD with eGFR ≥20 mL/min/1.73 m² (cardiorenal protection, independent of diabetes) — PBS Authority Required
Heart failure with reduced ejection fraction (HFrEF) — PBS Authority Required

Bicarbonate Reclamation

Approximately 85% of filtered HCO₃⁻ is reabsorbed in the proximal tubule via the following mechanism:

Luminal H⁺ secretion via NHE3 (and H⁺-ATPase) combines filtered HCO₃⁻ with H⁺ to form H₂CO₃.
Membrane-bound carbonic anhydrase IV (CA-IV) rapidly converts H₂CO₃ → CO₂ + H₂O.
CO₂ diffuses into the cell and is reconverted to HCO₃⁻ + H⁺ by intracellular carbonic anhydrase II (CA-II).
HCO₃⁻ exits the basolateral membrane via Na⁺/HCO₃⁻ co-transporter (NBCe1-A) into peritubular capillary blood.

The H⁺ secreted intracellularly is recycled via NHE3. The net effect is HCO₃⁻ reclamation without net acid excretion (that occurs primarily in the collecting duct via type A intercalated cells).

⚠️

Acetazolamide (Diamox®) — carbonic anhydrase inhibitor: By inhibiting CA-IV and CA-II, acetazolamide blocks proximal HCO₃⁻ reclamation, causing bicarbonaturia, metabolic acidosis (hyperchloraemic normal anion gap), and alkaline urine. Used clinically for altitude sickness (PBS-listed), glaucoma, idiopathic intracranial hypertension, and as a metabolic alkalosis-correction adjunct. Avoid in severe renal impairment (eGFR <30) — reduced efficacy. Dose: 250 mg PO OD–BD; paediatric: 5 mg/kg/dose BD–TDS.

Amino Acid Reabsorption

Filtered amino acids are almost completely reabsorbed in the proximal tubule via a variety of Na⁺-dependent and Na⁺-independent co-transporters. Specific transporter defects cause distinct aminoacidurias:

Disorder	Defective Transporter	Amino Acids Lost	Clinical Features
Cystinuria	rBAT/b⁰,⁺AT (SLC3A1/SLC7A9)	Cystine, lysine, ornithine, arginine	Cystine kidney stones (hexagonal crystals). Managed with hydration >3 L/day, urinary alkalinisation (potassium citrate), tiopronin (not PBS-listed).
Hartnup disease	B⁰AT1 (SLC6A19)	Neutral amino acids (tryptophan, etc.)	Pellagra-like rash, cerebellar ataxia (variable). Nicotinamide supplementation.
Fanconi syndrome (generalised)	Multiple proximal transporters	All amino acids, glucose, phosphate, HCO₃⁻, urate	Causes: tenofovir, ifosfamide, multiple myeloma, Wilson disease. Rickets/osteomalacia in children.

Proximal Tubular Drug Secretion

The proximal tubule secretes many drugs and toxins via organic anion transporters (OAT1/3) and organic cation transporters (OCT2/MATE):

OAT1/3 substrates: Penicillins, cephalosporins, methotrexate, furosemide, NSAIDs, probenecid (competitively inhibits OATs — used historically to prolong penicillin levels).
OCT2/MATE substrates: Metformin, cisplatin, trimethoprim, cimetidine, procainamide.
Cisplatin uptake via OCT2 contributes to nephrotoxicity; MATE variants affect renal clearance of metformin (relevant to T2DM patients with CKD).

Loop of Henle & Distal Tubule

Thin Descending Limb

The thin descending limb is highly permeable to water (via AQP1 channels) and moderately permeable to urea and small solutes, but relatively impermeable to NaCl. As tubular fluid descends into the hypertonic medullary interstitium, water is osmotically extracted, concentrating the luminal fluid to ~1200 mOsm/kg at the hairpin turn. This is a passive process — no active transport occurs in this segment.

Thin Ascending Limb

The thin ascending limb is impermeable to water but permeable to NaCl, which passively diffuses out along the concentration gradient established by the descending limb. This contributes to the countercurrent multiplication process.

Thick Ascending Limb (TAL) — The Diluting Segment

The TAL is the pharmacological target of loop diuretics and the primary generator of the medullary osmotic gradient.

NKCC2 (Na⁺-K⁺-2Cl⁻) Co-transporter

The apical NKCC2 (SLC12A1) transporter is the dominant mechanism for NaCl reabsorption in the TAL. It transports 1 Na⁺, 1 K⁺, and 2 Cl⁻ from the lumen into the cell:

Reabsorbs ~25% of filtered NaCl.
The TAL is impermeable to water — hence the tubular fluid becomes progressively diluted (hence "diluting segment").
NaCl reabsorption without water generates the corticomedullary osmotic gradient (300 → 1200 mOsm/kg).
ROMK (renal outer medullary K⁺) channels recycle K⁺ back into the lumen, generating a lumen-positive transepithelial voltage that drives paracellular reabsorption of Ca²⁺, Mg²⁺, Na⁺, and K⁺.

💊

Furosemide (Frusemide)

Urex®, Lasix® · Loop diuretic · NKCC2 inhibitor

Adult dose 20–80 mg PO/IV OD, titrate to response. Heart failure: 40–160 mg/day. Acute pulmonary oedema: 40–80 mg IV bolus.

Paediatric dose 0.5–2 mg/kg/dose PO/IV; max 6 mg/kg/day. Neonates: 0.5–1 mg/kg/dose.

Route Oral, IV, IM

Renal adjustment Higher doses may be required in CKD (reduced tubular secretion). IV preferred when eGFR <30.

PBS status ✔ PBS General Benefit

💊

Bumetanide

Burinex® · Loop diuretic · NKCC2 inhibitor

Adult dose 0.5–2 mg PO OD; IV: 1–2 mg. ~40× more potent than furosemide on a mg basis.

Renal adjustment Dose increase in CKD (up to 5 mg PO).

PBS status ✔ PBS General Benefit

Bartter Syndrome — NKCC2 & ROMK Defects

Inactivating mutations in TAL transporters cause Bartter syndrome, a group of inherited salt-wasting tubulopathies phenotypically resembling chronic loop diuretic use:

Type	Gene/Protein	Features
Type 1	SLC12A1 (NKCC2)	Antenatal, polyhydramnios, nephrocalcinosis
Type 2	KCNJ1 (ROMK)	Antenatal; transient hyperkalaemia then hypokalaemia
Type 3 (classic)	CLCNKB (ClC-Kb)	Later onset; hypokalaemia, metabolic alkalosis, hypercalciuria

Distal Convoluted Tubule (DCT)

The DCT reabsorbs approximately 5% of filtered NaCl via the apical NCC (Na⁺-Cl⁻ co-transporter, SLC12A3) — the target of thiazide diuretics. The DCT is also a major site of Ca²⁺ reabsorption via TRPV5 channels (stimulated by parathyroid hormone and calcitriol).

💊

Hydrochlorothiazide

Dithiazide® · Thiazide diuretic · NCC inhibitor

Adult dose 12.5–50 mg PO OD. Hypertension: 12.5–25 mg OD typical. Nephrolithiasis (hypercalciuria): 25–50 mg OD.

Paediatric dose 1–2 mg/kg/day PO in 1–2 divided doses (nephrogenic DI, nephrolithiasis).

Renal adjustment Ineffective when eGFR <30 mL/min/1.73 m² — consider metolazone or loop diuretic instead.

PBS status ✔ PBS General Benefit

Gitelman Syndrome — NCC Defect

Loss-of-function mutations in SLC12A3 (NCC) cause Gitelman syndrome — the most common inherited salt-wasting tubulopathy (prevalence ~1:40,000). Features include hypokalaemia, metabolic alkalosis, hypomagnesaemia, hypocalciuria, and typically presents in adolescence/adulthood. Phenotypically resembles chronic thiazide use. Management: K⁺ and Mg²⁺ supplementation, spironolactone if refractory hypokalaemia.

Juxtaglomerular Apparatus (JGA)

The JGA consists of three cell types that integrate the tubuloglomerular feedback and renin-angiotensin system:

Granular (JG) cells: Modified smooth muscle cells in the afferent arteriolar wall that synthesise, store, and secrete renin. Stimuli: ↓ renal perfusion pressure, ↓ macula densa NaCl, β₁-adrenergic stimulation, PGE₂.
Macula densa cells: Sense luminal [NaCl] via NKCC2 and modulate both afferent arteriolar tone and renin release.
Extraglomerular mesangial (lacis) cells: Transmit signals between macula densa and granular cells.

Collecting Duct & Countercurrent Mechanism

The collecting duct is the final site of urine modification, responsible for fine-tuning Na⁺, K⁺, H⁺, and water excretion under hormonal control. It traverses the medullary osmotic gradient generated by the loop of Henle, enabling both dilute and concentrated urine production.

Principal Cells — Na⁺, K⁺, and Water Handling

Principal cells constitute ~65–70% of collecting duct epithelium and express:

ENaC (epithelial Na⁺ channel): Apical; mediates electrogenic Na⁺ reabsorption. Stimulated by aldosterone (via mineralocorticoid receptor → SGK1 → ENaC membrane insertion) and ADH. Blocked by amiloride and triamterene.
ROMK and BK (big-K⁺) channels: Apical; mediate K⁺ secretion. Aldosterone and high tubular flow rates enhance K⁺ secretion (relevant to K⁺-sparing vs K⁺-wasting diuretic effects).
Aquaporin-2 (AQP2): Apical; ADH (vasopressin, AVP)-regulated water channel. AVP binds V2 receptors on the basolateral membrane → cAMP → PKA → AQP2 vesicle insertion into apical membrane → water reabsorption. AQP3 and AQP4 are constitutively expressed on the basolateral membrane.

Intercalated Cells — Acid-Base Handling

Cell Type	Function	Key Transporters	Stimulus
Type A (α) intercalated cell	H⁺ secretion (net acid excretion)	Apical H⁺-ATPase, H⁺/K⁺-ATPase; basolateral Cl⁻/HCO₃⁻ exchanger (AE1/Band 3)	Acidosis, aldosterone, hypokalaemia
Type B (β) intercalated cell	HCO₃⁻ secretion	Apical Cl⁻/HCO₃⁻ exchanger (pendrin); basolateral H⁺-ATPase	Alkalosis, hypochloraemia
Non-A, non-B intercalated cell	Both H⁺ and HCO₃⁻ secretion	Expresses both pendrin and H⁺-ATPase	Transitional state

Aldosterone Actions — Clinical Pharmacology

Aldosterone, synthesised in the zona glomerulosa of the adrenal cortex, acts on principal cells and intercalated cells via the mineralocorticoid receptor (MR):

↑ ENaC expression → ↑ Na⁺ reabsorption → ↑ ECF volume → ↑ blood pressure
↑ ROMK expression → ↑ K⁺ secretion → hypokalaemia risk
↑ H⁺-ATPase in type A intercalated cells → metabolic alkalosis

💊

Spironolactone

Aldactone®, Spiractin® · Mineralocorticoid receptor antagonist

Adult dose Heart failure (HFrEF): 25–50 mg PO OD (RALES/EHCRUS trials). Hyperaldosteronism: 25–200 mg/day. Ascites: 100–400 mg/day.

Renal adjustment Avoid if eGFR <30 (hyperkalaemia risk). Monitor K⁺ closely if eGFR 30–60.

PBS status ✔ PBS General Benefit

💊

Amiloride

Midamor® · ENaC blocker (K⁺-sparing diuretic)

Adult dose 5–10 mg PO OD. Often combined with hydrochlorothiazide (Moduretic®).

Renal adjustment Contraindicated if eGFR <30 (hyperkalaemia risk).

PBS status ✔ PBS General Benefit

ADH (Vasopressin) — Water Balance

ADH (arginine vasopressin, AVP) is synthesised in the hypothalamic supraoptic and paraventricular nuclei, stored in the posterior pituitary, and released in response to:

↑ Plasma osmolality (detected by hypothalamic osmoreceptors; threshold ~280 mOsm/kg)
↓ Effective circulating volume (detected by baroreceptors in carotid sinus, aortic arch, left atrium)
Angiotensin II, pain, nausea, certain drugs

ADH binds V2 receptors on the collecting duct principal cell basolateral membrane → Gs → adenylyl cyclase → ↑ cAMP → PKA → AQP2 phosphorylation and insertion into apical membrane → water reabsorption → concentrated urine. ADH also stimulates urea transporter UT-A1 in the inner medullary collecting duct, enhancing urea recycling and medullary concentration capacity.

💊

Desmopressin (DDAVP)

Desmotabs®, Minirin® · V2 receptor agonist (synthetic AVP analogue)

Adult dose Central DI: 100–400 µg PO nocte; or 10–40 µg intranasal nocte. Nocturnal enuresis: 200–400 µg PO nocte. vWF/haemophilia: 0.3 µg/kg IV.

Paediatric dose Central DI: 50–300 µg PO nocte; intranasal: 5–30 µg nocte. Enuresis: 120–240 µg PO nocte.

PBS status ✔ PBS General Benefit (oral, intranasal)

Liddle Syndrome — ENaC Gain-of-Function

Activating mutations in ENaC subunits (SCNN1B, SCNN1G) cause Liddle syndrome — a rare autosomal dominant form of early-onset hypertension characterised by:

Hypertension (often severe, presenting in adolescence/young adulthood)
Hypokalaemia, metabolic alkalosis
Low renin and low aldosterone (suppressed by volume expansion)
Treatment: amiloride (directly blocks ENaC) — not spironolactone (aldosterone is already suppressed)

Countercurrent Multiplication & Exchange

The corticomedullary osmotic gradient (300 → 1200 mOsm/kg) is established by the countercurrent multiplication system and preserved by the countercurrent exchange system:

Countercurrent Multiplication (Loop of Henle)

Single effect: NKCC2 in the TAL actively pumps NaCl into the interstitium (without water, as TAL is water-impermeable), creating a ~200 mOsm/kg transepithelial gradient.
Multiplication: The hairpin turn of the loop allows the ascending and descending limbs to operate in a countercurrent arrangement, multiplicatively amplifying the single effect along the corticomedullary axis.
Urea recycling: ADH-stimulated UT-A1 in the inner medullary collecting duct allows urea to enter the medullary interstitium, contributing ~50% of the inner medullary osmolality. Urea then re-enters the thin descending limb via UT-A2, completing the recycling loop.

Countercurrent Exchange (Vasa Recta)

The vasa recta are specialised peritubular capillaries that run parallel to the loops of Henle in the medulla. Their hairpin configuration and high permeability to solutes and water allow them to supply oxygen and nutrients to the medulla without dissipating the osmotic gradient:

Descending vasa recta: blood gains solute (NaCl, urea) and loses water as it descends into the hypertonic medulla.
Ascending vasa recta: blood loses solute and gains water as it returns toward the cortex.
Net effect: medullary blood flow washes out only a small fraction of the gradient, preserving concentrating ability.

⚠️

Clinical relevance — medullary washout: Conditions that increase medullary blood flow (e.g., osmotic diuresis from hyperglycaemia, mannitol infusion, CKD with solute overload) impair countercurrent exchange and reduce maximal concentrating ability. This is why poorly controlled diabetic patients often have impaired urinary concentration despite intact ADH secretion. Conversely, loop diuretics (furosemide) abolish the single effect by inhibiting NKCC2, directly destroying the medullary gradient and causing an isosthenuric urine (~300 mOsm/kg).

Diabetes Insipidus — Collecting Duct Water Handling

Partial DI

Mild Concentrating Defect

Urine osmolality 300–500 mOsm/kg. Polydipsia; polyuria may be moderate (2–4 L/day). Often compensated by intact thirst mechanism.

Setting: Outpatient monitoring; desmopressin trial if symptomatic

Complete Central DI

ADH Deficiency

Urine osmolality <300 mOsm/kg (often <200). Polyuria >3 L/day (often 5–20 L). Plasma osmolality elevated. Responds to desmopressin (↑ Uosm >50%).

Setting: Endocrine referral; MRI pituitary/hypothalamus

Complete Nephrogenic DI

Renal Resistance to ADH

Urine osmolality <300 despite elevated AVP. No response to desmopressin. Causes: lithium (20–40% of chronic users), hypercalcaemia, hypokalaemia, genetic (AVPR2/AQP2 mutations).

Setting: Nephrology referral; treat underlying cause; thiazides + amiloride for symptom management

Special Populations

🤰 Pregnancy

GFR & renal physiology

GFR increases 40–60% by the second trimester (peaking ~140 mL/min/1.73 m²) due to renal plasma flow increase from progesterone-mediated vasodilation. Serum creatinine falls to ~35–50 µmol/L — values >70 µmol/L may indicate renal impairment in pregnancy.

Diuretic use

Thiazides may be continued for chronic hypertension (RANZCOG guidelines). Furosemide generally avoided. ACE inhibitors/ARBs contraindicated (fetotoxic — oligohydramnios, renal dysplasia, IUGR).

Tubular function changes

Lower serum HCO₃⁻ (20–22 mmol/L) from respiratory alkalosis (progesterone-driven hyperventilation). Mild glycosuria common despite normal glucose (reduced T_m for glucose). Proteinuria >300 mg/day requires investigation for pre-eclampsia.

👶 Paediatrics

Neonatal renal immaturity

GFR at term birth: ~20–40 mL/min/1.73 m²; reaches adult values by 1–2 years. Premature infants have even lower GFR. Reduced concentrating ability (max ~600–700 mOsm/kg in neonates vs ~1200 in adults) due to short loops of Henle and reduced medullary gradient. High susceptibility to dehydration.

Drug dosing

Many drugs require weight-based dosing and extended intervals in neonates/infants due to immature tubular secretion (OAT, OCT transporters). Gentamicin interval extension in neonates reflects immature glomerular and tubular function.

Inherited tubulopathies

Bartter syndrome (antenatal presentation with polyhydramnios), Gitelman syndrome (adolescent presentation), Liddle syndrome (early-onset hypertension). Genetic testing available through Australian public genomics services.

👴 Elderly

Age-related changes

GFR declines ~0.75–1 mL/min/year after age 40. Reduced concentrating and diluting ability. Lower renal plasma flow from arteriosclerosis. Sarcopenia masks renal impairment (low creatinine production → normal serum creatinine despite reduced GFR — use cystatin C if uncertain).

Prescribing caution

High risk of AKI from "triple whammy" (ACEi + NSAID + diuretic). Use NSAIDs sparingly or avoid. Dose-adjust renally cleared medications per AMH. Monitor electrolytes regularly (K⁺, Na⁺) when initiating diuretics, ACEi/ARBs, or potassium supplements.

🩺 Chronic Kidney Disease

Tubular adaptations in CKD

Residual nephrons undergo compensatory hyperfiltration and increased solute delivery per nephron. This preserves total GFR temporarily but accelerates nephron loss. Adaptations include increased proximal Na⁺ reabsorption and enhanced distal K⁺ secretion (maintaining normokalaemia until CKD Stage 5).

Diuretic selection

Loop diuretics remain effective in CKD (dose escalation required). Thiazides lose efficacy when eGFR <30 (exception: metolazone retains some efficacy in severe CKD). Combination loop + thiazide ("sequential nephron blockade") for refractory oedema — monitor closely for hypokalaemia, hyponatraemia, and AKI.

🛡️ Immunocompromised

Nephrotoxic agents

Immunocompromised patients are frequently exposed to nephrotoxic drugs: calcineurin inhibitors (cyclosporin, tacrolimus) cause afferent arteriolar vasoconstriction; aminoglycosides cause proximal tubular necrosis; amphotericin B (including liposomal) causes distal nephron toxicity. Tenofovir DF causes proximal tubular injury (Fanconi syndrome) — use TAF (tenofovir alafenamide) if available on PBS.

Monitoring

Baseline and serial eGFR, serum K⁺, Mg²⁺, phosphate. Spot urine protein:creatinine ratio (uPCR) for subclinical nephrotoxicity detection.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

CKD burden

Aboriginal and Torres Strait Islander peoples experience CKD at 2–3 times the rate of non-Indigenous Australians, with ESKD incidence 4–8 times higher and onset approximately 20 years earlier (AIHW, 2023). Understanding tubular physiology is essential for appropriate prescribing and early detection of tubular injury.

Acute rheumatic fever & RHD

Rheumatic heart disease (RHD) remains prevalent in remote and northern Australian Indigenous communities. Long-term secondary prophylaxis with benzathine penicillin G requires awareness of renal penicillin clearance. Heart failure from RHD may require loop diuretics — dose adjustment in concurrent CKD is critical.

Diabetes & SGLT2 inhibitors

Type 2 diabetes prevalence is 3–4 times higher in Indigenous Australians and is the leading cause of CKD. SGLT2 inhibitors (dapagliflozin, empagliflozin) are PBS-listed for CKD from eGFR ≥20 — ensuring equitable access through Aboriginal Medical Services (AMS) is a priority. The Kidney Health Australia CKD guidelines recommend annual eGFR and uACR screening for all Indigenous adults with diabetes from diagnosis.

Remote & rural access

Specialist nephrology services are concentrated in major cities. Remote communities rely on telehealth nephrology, visiting specialist clinics, and primary care physicians supported by Aboriginal Health Workers/Practitioners. Point-of-care creatinine testing (e.g., i-STAT) enables rapid eGFR estimation in communities without laboratory access.

Medication safety

Ensure eGFR-based dose adjustment for renally cleared medications is performed at every prescribing encounter. Avoid nephrotoxic combinations (triple whammy) — this is especially important given the high prevalence of concurrent NSAID use, ACEi/ARB therapy, and diuretic use in managing hypertension and heart failure in Indigenous communities. Culturally safe medication education from Aboriginal Health Workers improves adherence.

Cultural safety

Engage with local Aboriginal Community Controlled Health Organisations (ACCHOs). Provide education about kidney health using culturally appropriate resources (Kidney Health Australia Indigenous resources). Respect Sorry Business and family-centred decision-making in chronic disease management plans. Integrate renal health checks into 715 Health Checks (MBS Item 715).

Clinical Correlations & Prescribing Implications

A thorough understanding of renal physiology enables rational prescribing, anticipation of drug effects, and early recognition of tubulopathies. The following table summarises the key nephron segment–drug interactions:

Nephron Segment	Key Transporter	Drug Target	Clinical Effect
Proximal tubule	SGLT2	Dapagliflozin, empagliflozin	Glycosuria, natriuresis, cardiorenal protection
Proximal tubule	CA-IV / CA-II	Acetazolamide	Bicarbonaturia, metabolic acidosis
TAL	NKCC2	Furosemide, bumetanide	Natriuresis, K⁺ wasting, gradient destruction
DCT	NCC	Hydrochlorothiazide, indapamide	Natriuresis, ↑ Ca²⁺ reabsorption, hypokalaemia
Collecting duct	ENaC	Amiloride, triamterene	Na⁺ wasting, K⁺ sparing
Collecting duct	MR	Spironolactone, eplerenone	Na⁺ wasting, K⁺ sparing, anti-fibrotic
Collecting duct	AQP2 (via V2R)	Desmopressin	Water retention, concentrated urine

Quick Reference — Diuretic Strategy in CKD

eGFR ≥30

Thiazide + Loop diuretic if needed

Thiazides effective

Monitor K⁺, Na⁺, Mg²⁺

eGFR 15–30

Loop diuretic (high dose) ± metolazone

Thiazides largely ineffective

Metolazone 2.5–10 mg PO; monitor closely

eGFR <15 / Dialysis

High-dose furosemide (IV if needed)

Residual urine output variable

Fluid restriction more important than diuretics

<